Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive disease caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX). CoQ 10 deficiency has been identified in fibroblasts and muscle of AOA1 patients carrying the common W279X mutation, and aprataxin has been localized to mitochondria in neuroblastoma cells, where it enhances preservation of mitochondrial function. In this study, we show that aprataxin deficiency impairs mitochondrial function, independent of its role in mitochondrial DNA repair. The bioenergetics defect in AOA1-mutant fibroblasts and APTX-depleted Hela cells is caused by decreased expression of SDHA and genes encoding CoQ biosynthetic enzymes, in association with reductions of APE1, NRF1 and NRF2. The biochemical and molecular abnormalities in APTXdepleted cells are recapitulated by knockdown of APE1 in Hela cells and are rescued by overexpression of NRF1/2. Importantly, pharmacological upregulation of NRF1 alone by 5-aminoimidazone-4-carboxamide ribonucleotide does not rescue the phenotype, which, in contrast, is reversed by the upregulation of NRF2 by rosiglitazone. Accordingly, we propose that the lack of aprataxin causes reduction of the pathway APE1/NRF1/NRF2 and their target genes. Our findings demonstrate a critical role of APTX in transcription regulation of mitochondrial function and the pathogenesis of AOA1 via a novel pathomechanistic pathway, which may be relevant to other neurodegenerative diseases.
Introduction
Ataxia oculomotor apraxia type 1 (AOA1) is an autosomal recessive cerebellar disease characterized by early-onset cerebellar ataxia, oculomotor apraxia, absence of tendon reflexes, distal loss of sense of position and vibration, and pyramidal weakness of the legs and peripheral neuropathy, often associated with hypoalbuminemia, hypercholesterolemia and mental retardation (1) (2) (3) (4) (5) (6) .
AOA1 is caused by mutations in APTX, which encodes the DNA strand-break repair protein aprataxin (APTX) (7, 8) . Cell lines derived from AOA1 patients show enhanced sensitivity to a range of DNA damaging agents that generate single-strand breaks (SSBs) such as hydrogen peroxide (9) , indicating a role for APTX in the cellular response to DNA damage and oxidative stress. The hypersensitivity to agents inducing oxidative DNA damage may be attributed to interactions of APTX with proteins involved in cellular response to oxidative damage (10) . However, unlike Ataxia-Telangiectasia (A-T), A-T-like disorders, xeroderma pigmentosum or other autosomal recessive cerebellar ataxias caused by DNA repair or maintenance defects, AOA1 patients do not manifest immunodeficiency or cancer susceptibility (11) . Furthermore, assessments of DNA strand-break repair in AOA1 human fibroblasts and different APTX −/− mouse cell lines have produced conflicting results (9, (12) (13) (14) (15) , suggesting that factors other than nuclear DNA damage may be involved in the pathogenesis of this disease. Aprataxin also is thought to regulate transcription via RNA binding (16) , interactions with RNA binding proteins, nucleolar distribution and delocalization after transcription inhibition (17) . Nevertheless, despite manifesting significant decrease in nucleolar staining of nucleolin, fibroblasts carrying the common APTX W279X mutation did not show defects in rRNA transcription (17) .
Interestingly, in muscle and/or fibroblasts of patients with AOA1 carrying the stop-codon mutation p.W279X, we and other investigators have observed decreased levels of coenzyme Q 10 (ubiquinone, CoQ 10 ), an antioxidant and electrons transporter, which carries electrons from Complexes I (NADH dehydrogenase) and II [succinate dehydrogenase (SDH)] to Complex III (cytochrome bc1 complex) of the mitochondrial respiratory chain (5, (18) (19) (20) . In AOA1 patients, supplementation with CoQ 10 was associated with increased strength and energy level and disappearance of seizures in the affected individuals (18, 21) , suggesting a role of CoQ 10 deficiency in the pathogenesis of AOA1.
Recently, the role of aprataxin in the maintenance of mitochondrial DNA (mtDNA) has been investigated. Sykora and colleagues showed that APTX also localizes to mitochondria and that depletion of APTX in human SH-SY5Y neuroblastoma cells and primary skeletal muscle myoblasts results in reduced activity of citrate synthase (CS) (an index of mitochondrial mass), mtDNA damage and decreased mtDNA copy number (22) .
However, the mechanisms underlying CoQ 10 deficiency secondary to APTX mutations remain elusive. In this work, we show that mitochondrial dysfunction, including CoQ 10 deficiency, in W279X-mutant fibroblasts from AOA1 patients and APTX-depleted Hela cells is independent of APTX role in nuclear or mtDNA repair and is mediated by downregulation of genes encoding mitochondrial proteins, including enzymes involved in CoQ 10 biosynthesis, via APE1, NRF1 and NRF2.
Results

APTX-mutant fibroblasts show reduced levels and biosynthesis of CoQ 10
We previously reported low levels of CoQ 10 in three AOA1 fibroblasts (P1, P2 and P3) (18) . Therefore, we measured CoQ 10 levels in six additional fibroblasts cell lines carrying different APTX mutations. In total, five homozygous p.W279X-mutant cell lines (P1, P2, P5, P7 and P9) and two compound heterozygous ( p.W279X/p.Q181X; p.W279X/unknown mutation) cell lines (P8 and P3) showed decreased levels of CoQ 10 (Table 1) . One cell line, homozygous for the common mutation p.W279X (P6), and one cell line harboring another homozygous stop-codon mutation (p.R306X/p.R306X) (P4) showed normal levels of CoQ 10 (Table 1) .
To define the cause of CoQ 10 deficiency, we studied the biosynthesis of CoQ 10 in the seven cell lines with reduced CoQ 10 levels, using two different assays. First, using 14 C-PHB as a substrate, we analyzed the activity of the condensation of para- 
APTX-mutant fibroblasts show reduced succinate dehydrogenase
To address whether CoQ 10 deficiency was associated with other mitochondrial abnormalities, we assessed respiratory chain enzymes activities and mitochondrial mass in patients' fibroblasts with decreased levels of CoQ 10 . As CoQ 10 transfers electrons from Complexes I and II to Complex III, we measured Complex I + III and II + III activities, and we observed mild decrease in Complex I + III activities (61 ± 7% of controls) (Fig. 1A) , consistent with the mild CoQ 10 deficiency, and normal Complex II + III activities (controls: 100 ± 9%, patients: 100 ± 10%). In contrast, SDH (Complex II) activity was significantly reduced (63 ± 9% of controls, Fig. 1B) , and SDH protein levels were reduced, although not significantly (71 ± 9% of controls, Fig. 2A ).
CS activity (89 ± 9% of controls, Fig. 1C ) and TOM20 levels (controls: 100 ± 9%, patients: 86 ± 12%), two indices of mitochondrial mass and mtDNA copy number (controls: 100 ± 9%, patients: 105 ± 12%) were comparable in mutant and control fibroblasts. Therefore, the low levels of CoQ 10 , Complex I + III activity and Complex II in APTX-mutant fibroblasts are not caused by reduced mitochondrial content.
APTX-mutant fibroblasts manifest reduced cell respiratory control ratio
In order to assess the metabolic consequences of the mitochondrial abnormalities observed, we assessed the energy metabolism in CoQ 10 -deficient fibroblasts. Adenosine triphosphate (ATP) turnover, expressed as coupling efficiency, showed no differences between control and APTX-mutant fibroblasts. However, respiratory control ratio was reduced in AOA1 cells with decreased CoQ 10 and Complex II (62 ± 19% of controls) relative to controls (Fig. 1D) . In contrast, an AOA1 cell line with normal CoQ 10 and Complex II (P4) behaved as controls. The diminished cell respiratory control ratio reflects defective electron transport through the respiratory chain Complexes I-IV and may be caused by both decreased CoQ 10 , which shuttles electrons between Complexes I and II to III, and low Complex II activity.
Aprataxin knockdown in Hela cells recapitulates the phenotype of AOA1-mutant fibroblasts
To further investigate the function of APTX, we used shRNAmediated knockdown in Hela cells. The sequence of the selected shRNA (TRCN0000083642) interfered expression of nuclear and mitochondrial aprataxin isoforms. Clones with <20% of wildtype levels of APTX transcript (17 ± 5% of controls) and protein (24 ± 5% of controls) were chosen to verify the effects of lack of APTX.
Aprataxin-depleted Hela cells did not show growth defects or changes in morphology. The levels of CoQ 10 were significantly decreased in the APTX-interfered clones compared with those expressing only scramble shRNA (shScramble: 100 ± 11%; shAPTX 71 ± 8%). Consistently, Complex I + III activities were mildly decreased in APTX knockdown cells (81 ± 12% of controls) compared with control cell lines (Fig. 1F) , and Complex II + III activity was comparable in knockdown and control cell lines (shScramble: 100 ± 14%, shAPTX: 105 ± 12%).
As in mutant fibroblasts, SDH (Complex II) activity and protein level were reduced in APTX-depleted cells (64 ± 9 and 75 ± 4% of controls) (Figs 1G and 2B), and CS activity was normal (Fig. 1H) . Surprisingly, significant increase in mtDNA levels (shScramble: 100 ± 9, shAPTX: 120 ± 4%) and in TOM20 protein levels (shScramble: 100 ± 9, shAPTX: 138 ± 11%) were observed.
APTX-mutant fibroblasts and APTX-depleted cells show reduced mRNA expression and protein levels of PDSS1, the first committed enzyme of CoQ 10 biosynthesis
As the radioactive biosynthetic assays in APTX-mutant fibroblasts with low CoQ 10 indicated a defect in CoQ 10 biosynthesis, we investigated the steps of CoQ 10 biosynthesis in the CoQ 10 -deficient cell lines, by measuring mRNA and protein levels of the 12 known enzymes known to be involved in the CoQ 10 synthetic pathway and/or its regulation.
Fibroblasts with the p.W279X mutation and low levels of CoQ 10 showed significantly reduced expression of PDSS1 (60 ± 6% of controls), a subunit of the first committed enzyme of the CoQ 10 biosynthetic pathway (Fig. 3A) , consistent with the reduction in CoQ 10 levels and biosynthesis observed in the same cell lines. In contrast, P4 and P6, which had normal levels of CoQ 10 , had normal PDSS1 mRNA levels (P4 = 115 ± 20% and P6 = 124 ± 17% of controls) and normal or increased mRNA levels of the other enzymes of the pathway (Supplementary Material, Fig. S1 ).
Reduced PDSS1 mRNA expression in patient fibroblasts correlated with decreased PDSS1 protein levels (40 ± 5% of controls) (Fig. 3B ). PDSS1 mRNA and protein levels were also significantly decreased in APTX-depleted Hela cells, compared with wildtype cells (73 ± 6 and 64 ± 4% of controls) ( Fig. 3C and D) . The decrease of PDSS1, the first committed enzyme of CoQ 10 biosynthetic pathway, which catalyzes elongation of GPP or FPP with several IPP groups to form the decaprenyl chain, accounts for the reduced incorporation of 14 C-PHB into AOA1 cells. To exclude the possibility of PDSS1 mutations causing reduction in mRNA and encoded protein, we sequenced exons and flanking intronic regions of PDSS1 in one AOA1 patient (P3) and did not find any alterations.
Levels of APE1 are reduced in APTX-mutant and APTX-depleted cells
Because APTX interacts with a variety of proteins through the forkhead-associated (FHA) domain, we initially excluded a direct interaction between APTX and PDSS1 protein by co-immunoprecipitation. Then, we analyzed the levels of APE1 and PARP-1, two interacting partners of aprataxin involved in mitochondrial function (23) (24) (25) .
AOA1 fibroblasts with CoQ 10 deficiency showed decreased levels of APE1 (77 ± 5% of controls) (Fig. 4A) , and not statistically significant decrease of PARP-1 (controls: 100 ± 11, patients: 68 ± 5% of controls), whereas AOA1 cells with normal CoQ 10 levels (P4 and P6) had normal amounts of APE1 and PARP1 (P4: APE1 106 ± 5% and PARP-1 103 ± 2%; P6: APE1 119 ± 28% and PARP-1 99.8 ± 14% of controls). In APTX-depleted Hela cells, only APE1 was reduced (67 ± 11% of controls) (Fig. 4D ), whereas PARP1 remained unaltered (shScramble: 100 ± 9%, shAPTX: 102 ± 10%). Therefore, decreased APE1 level is a shared feature of W279X-mutant and APTX knockdown cells with low CoQ 10 , suggesting a role of this protein in the pathogenesis of mitochondrial abnormalities in APTX-mutant and APTX-depleted cells. 2945.4 ± 195 DPM/mg prot/day 100 ± 6.6 Patients (n = 7)
1796.3 ± 54 DPM/mg prot/day 61.0 ± 1. Values are expressed as mean ± SEM.
Nuclear respiratory factors 1 and 2 are reduced in APTX-mutant and APTX-depleted cells
Multiple mitochondrial genes, including succinate dehydrogenase subunit A (SDHA), are co-regulated by NRF1 and NRF2 (26, 27) , and published studies have shown that mitochondrial genes are downregulated in APE1-deficient cells (23, 28) owing to the regulatory role of APE1 on DNA-binding and transcriptional activity of NRF1. Therefore, we assessed steady-state levels of NRF1, and NRF2, in AOA1 fibroblasts and APTX-depleted cells.
Only the fibroblasts with at least one copy of the p.W279X mutation and APTX knockdown cells, which had low levels of CoQ 10 and APE1, showed decreased steady-state levels of both transcription factors (NRF1:67 ± 7%, NRF2:70 ± 3% of controls) ( Fig. 4B and C), consistent with the mild reduction of CoQ 10 and SDHA protein in these cells. In contrast, AOA1 fibroblasts without deficiency of CoQ 10 or complex II showed normal levels of NRF1 and NRF2 (P4: NRF1 103 ± 2% and NRF2 118 ± 13%; P6: NRF1 91 ± 22% and NRF2 84 ± 15% of controls).
We analyzed also the levels of PGC1α, a positive regulator of mitochondrial biogenesis and respiration (29) , which contributes to the detoxification of reactive oxygen species (ROS) and regulates NRF1 and NRF2 (30) (31) (32) . No reduction was observed in PGC1α protein in AOA1 cells (100 ± 24% of controls) or in APTXdepleted clones (93 ± 12% of controls), thereby we excluded reduction of PGC1α as the cause of the diminished levels of NRF1 and NRF2.
Of relevance, several NRF2-binding sites are located within the vicinity of PDSS1 (chr10:26 963 258-27 012 389) ( 
APE1 depletion impairs NRF1 expression in Hela cells and resembles APTX knockdown clones
To confirm the role of the lack of APE1 in the pathogenesis of mitochondrial abnormalities in APTX-depleted cells via NRF1/ NRF2, we knocked down APE1. ShRNA-mediated APE1 knockdown clones with 53 ± 11% of control protein levels showed lower levels of NRF1 transcript (43 ± 3% of controls) and protein (64 ± 10%) (Fig. 6 ). In addition, in those clones, we observed reduced expression of NRF2, PDSS1 and SDHA and protein levels ( Fig. 6 ) similar to the reductions found in APTX-depleted cells (Figs 2B, 3D and 4F), confirming that the lack of APE1 decreases NRF1 leading to the mitochondrial biochemical and molecular defects observed in APTX-mutant cells.
Overexpression of NRF1 increases PDSS1 and SDHA in APTX-depleted cells
To further validate the hypothesis that the reduction of NRF1, and, in turn, NRF2, causes mitochondrial respiratory impairment in APTX-depleted clones, we overexpressed NRF1 in APTXdepleted Hela cells. Different clones expressing high levels of NRF1 transcript and protein levels ( Fig. 7A and B) were assessed to determine effects on the expression of PDSS1, SDHA and COQ5 transcripts, and their protein levels ( Fig. 7C and D) . In addition, we measured the levels of NRF2 and TOM20 (Fig. 7D) . Stable transfection of NRF1 restored the normal level of NRF1 protein in APTX-depleted clones (Fig. 7B) . In contrast, NRF1 protein levels did not increase when NRF1 construct was expressed in control cells, suggesting a tight normal physiological regulation of NRF1 protein levels. Increased expression of NRF1 raised the levels of NRF2 protein in APTX knockdown cells, returning its value to levels comparable with control clones (Fig. 7D) . Also PDSS1, SHDA and COQ5 protein levels were increased in APTX-depleted clones expressing NRF1 compared with APTX-depleted clones with empty vectors (Fig. 7D) . Overexpression of NRF1 also increased the levels of CoQ 10 in the clones expressing NRF1 compared with controls (shScramble-EV: 100 ± 14%, shAPTX-EV: 81 ± 7%, shScramble-NRF1: 127 ± 26% and shAPTX-NRF1: 365 ± 103%). We did not observe an increase of TOM20 (Fig. 7D) or mtDNA in NRF1-expressing clones (shScramble-NRF1: 99 ± 3%, shAPTX-NRF1: 98 ± 2%). Thus, the upregulation of NRF2 mediated by overexpression of NRF1 complemented the molecular alterations observed in APTX-depleted Hela cells, indicating that deficiencies of both NRFs contribute to mitochondrial dysfunction in AOA1.
Rosiglitazone increases the expression of PDSS1 in AOA1 fibroblasts through NRF2
5-aminoimidazone-4-carboxamide ribonucleotide (AICAR) and rosiglitazone are two commercially available compounds, which have been shown to affect mitochondrial biogenesis and function through the upregulation of NRF1 and NRF2 (33) . Therefore, we treated AOA1 fibroblasts with these pharmaceutical agents to assess their impact on NRFs levels and downstream effects.
AICAR significantly increased NRF1 protein levels in AOA1-mutant fibroblasts (Fig. 8A ), but did not elevate PDSS1 levels. In contrast, rosiglitazone increased the levels of NRF2 and PDSS1 significantly (Fig. 8B) . SDHA and TOM20, two NRF1-targeted genes, showed trends toward increases after both treatment (Fig. 8A) . These results support the role of NRF2 in the transcriptional regulation of PDSS1 gene.
Discussion
We and other investigators have observed CoQ 10 deficiency secondary to mutations in aprataxin (5, (18) (19) (20) , a nuclear DNA-processing protein that hydrolyses 5′-adenylated DNA (12, 34, 35) , and, when mutated, causes the neurodegenerative disease AOA1. Although aprataxin predominantly resides in nuclei (9,10,14,36), in neural-like cells, it has also been localized to mitochondria where it has been shown to preserve mitochondrial function and to prevent accumulation of mtDNA damage (22) .
Here, we have observed that CoQ 10 deficiency in APTX-mutant and APTX-depleted cells is due to diminished CoQ 10 biosynthesis, and it is associated with reduced respiratory capacity, decreased mitochondrial respiratory chain enzymes and normal mtDNA content, suggesting that, despite the putative role of aprataxin in maintaining mtDNA integrity, mitochondrial dysfunction in APTX-depleted cells is not due to its involvement in mtDNA repair but rather is related to its role in transcription regulation, and consequent impairment of the APE1/NRFs pathway, which plays a critical role in the cross-talk between nucleus and mitochondria.
APE1, a binding partner of APTX, has been described as a dualfunction protein involved in base excision repair (BER), and in eukaryotic transcriptional regulation of gene expression (37) , probably as consequence of the redox co-activation of various transcription factors including NRF1 (23), a regulator of mitochondrial function and biogenesis (26) . It has been reported that decreased APE1 levels are associated with reduced NRF1 DNA-binding activity and consequent altered expression of downstream genes (23) . In this study, we show that APTX deficiency causes depletion of APE1 and leads to reduction of NRF1, which in turns downregulates NRF2, and the downstream targets SDHA and PDSS1, causing deficiencies of SDH and CoQ 10 . NRF2-binding sites regulate SHDA expression (38) and have been found in close proximity to PDSS1. Moreover, NRF2 target sequences are also present in other genes, such as PDSS2 and COQ5, which are reduced in APTX-depleted cells. Thus, we hypothesize that the mitochondrial alterations linked to downregulation of APE1 and NRF1 are mediated by the reduction of NRF2. This hypothesis is supported by the observation that the upregulation of NRF2 mediated by NRF1 overexpression ameliorates molecular and biochemical abnormalities in APTX-depleted cells, and treatment with rosiglitazone, an anti-diabetic drug, which increases NRF2 transcript, rescues the abnormal biochemical phenotype in AOA1 fibroblasts. In contrast, AICAR, which enhances NRF1 expression (33), does not ameliorate the mitochondrial defects in the APTX-mutant cells. The activation of NRF1 by AICAR is not a specific effect, because AICAR, through activation of AMPK (39) , acts on several other transcription factors, co-activators and co-repressors. This may explain why pharmacological upregulation of NRF1 through AICAR does not cause NRF2 upregulation, which we have observed after NRF1 overexpression. We have also excluded the possibility that the rescue is due to increased mitochondrial biogenesis, because multiple indeces of mitochondrial mass are unaltered after NRF1 overexpression.
We believe that APE1 plays a key role in regulating CoQ biosynthesis through PDSS1 and COQ5 in W278X-mutant and APTX-depleted cells, because APE1, PDSS1 and COQ5 levels are reduced in W279X-mutant cells with reduced CoQ 10 ; moreover, we found that P4 (homozygote R306X mutant) has normal levels of transcripts for biosynthetic genes, APE1 and NRFs. In contrast, P6 (homozygote W279X with normal CoQ 10 level) showed increased expression of all the biosynthetic genes, except PDSS1 and COQ5, and normal APE1 levels.
The bioenergetic defect observed in AOA1 could be caused by CoQ 10 deficiency, and consequent reduction in Complex I + III activities, or by SDH deficiency, which, although caused by different mechanism, is also a feature of Friedreich ataxia, another autosomal recessive ataxia (40) . Although we cannot account for the normal levels of Complex II + III activities, some studies indicate that CoQ is compartmentalized into two intracellular CoQ pools, one of which transfers electrons from the CI oxidation of the NADH to CIII (CoQ NAD ) and the other one transfers electrons from the CII oxidation of the FADH 2 to CIII (CoQ FAD ). CI, but not CII, physically interacts with CIII in the formation of supercomplexes, which contain the CoQ NAD pool, whereas CIII molecules that are free of interaction with CI are mainly responsible for CoQ FAD oxidization (41) . Thus, if CoQ 10 deficiency in AOA1 decreases CIII bound to CI (supercomplex) (42), increased free CIII will be available for CII and may be reflected by a normalization of the CII + III activity.
Although SDH and CoQ 10 deficiency were observed in both AOA1 fibroblasts and APTX-depleted Hela cells, only CS activity was slightly decreased in AOA1 fibroblasts, whereas the levels of mtDNA and TOM20 were significantly increased in APTX-depleted cells. The differences in these indices of mitochondrial mass between AOA1-mutant and APTX-depleted cells suggest cell type-specific stress response or compensatory mechanisms. CS has been noted to be reduced in APTX-depleted neuroblastoma cells (22) , possibly due to loss of dysfunctional mitochondria. The mild biochemical defects in mitochondrial respiratory chain activities, CoQ 10 level and oxidative phosphorylation observed in AOA1 fibroblasts may reflect more severe abnormalities in other tissues, as tissue specificity is frequently observed in mitochondrial disorders including the autosomal recessive cerebellar ataxia caused by ADCK3 mutations, the most common primary CoQ 10 deficiency (43) . ADCK3 is an atypical protein kinase that regulated CoQ biosynthesis and is the homolog of coq8 in yeast (44) . Previous studies of ADCK3-mutant fibroblasts demonstrated mild CoQ 10 deficiency and mitochondrial respiratory chain defects strikingly similar to those observed in APTXmutant cells, and have slightly increased ROS production and proteins and lipid oxidation when stressed with glucose-free medium (45) . Moreover, in some patients carrying ADCK3 mutations, CoQ 10 deficiency is limited to muscle and does not extend to fibroblasts further indicating tissue-specific effects (43) . However, the lack of studies of the cerebellum has precluded empirical testing of the hypothesized neuron-specific defects. Alternatively, the mild biochemical defects may be sufficient to damage vulnerable cells in the cerebellum in this chronic and slowly progressive disease.
While our observations that the mitochondrial dysfunctions in AOA1 fibroblasts are related to the instability of APE1 and the consequent reduction of NRF1 and NRF2 are important, further studies are necessary to address the mechanisms of interaction and stabilization of APE1 by APTX and to understand the role of other factors, such as potential genetic modifiers causing phenotype variability, in order to explain why not all AOA1 cells carrying the p.W279X mutation show mitochondrial impairment, because it has been previously shown that mutant APTX becomes unstable regardless of the mutation (9, 14, 46) .
Interestingly, in other neurodegenerative disorders caused by defects in proteins involved in DNA break repair, impairments of other nuclear-mitochondrial cross-talk pathways have been observed. Fang et al. reported hyper-activation of PARP-1, which causes NAD + -SIRT1-PGC-1α-UCP2 axis depression, and in turn, defective mitophagy (25) . However, we did not observe abnormal levels of PARP-1 and PGC1-α in APTX-mutant/depleted cells; therefore, we have excluded involvement of this pathway in AOA1. Defects in this or other pathways leading to downregulation of transcription factors involved in respiratory gene expression may account for secondary mitochondrial dysfunctions in other diseases. For example, mice lacking Hint2, a mitochondrial protein belonging to the histidine triad (HIT) superfamily to which aprataxin belongs, manifest accelerated hepatic steatosis, mitochondrial abnormalities, including CoQ 10 deficiency, and downregulation of genes encoding proteins involved in mitochondrial fusion and fission (47) . Defective CoQ biosynthesis has been found also in cells lacking mitofusin 2 (MNF2), associated with Charcot Marie Tooth type 2A disease (29) .
The mitochondrial abnormalities we observed in APTX-mutant and APTX-depleted cells may be downstream effects in response to genotoxic stress, because elevated levels of 8-oxo-dG and hypersensitivity to agent causing DNA SSBs have been observed in AOA1-mutant fibroblasts (9, 10, 13) .
In summary, our findings shed some light on the link between APTX and mitochondrial function, which may lead to better understanding of the pathogenesis of AOA1 and other degenerative disorders. Uncovering the contribution of altered nuclear-mitochondrial cross-talk pathways to mitochondrial dysfunction is important to identify targets for novel therapeutic approaches.
Materials and Methods
Cells culture and pharmacological treatment
All experiments were performed in human skin fibroblasts from at least three controls and six AOA1 patients (Table 1) , unless differently specified. Skin fibroblasts and Hela cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 5 ml MEM non-essential amino acids, 5 ml of MEM vitamin solution and 5 ml of penicillin-streptomycin (total volume 565 ml) until confluence. Cells were grown to perform each experiment in replicates.
AOA1 fibroblast cells were treated for 72 h either with 60 µ of rosiglitazone (ICS International Clinical Service GmbH, S2505; dissolved in DMSO) or 0.5 m of AICAR (Toronto Research Chemicals, A611700; dissolved in water) (33) or with the respective vehicle in regular medium. After the treatment, cells were collected and analyzed.
CoQ 10 level measurement
To measure CoQ 10 , cells were grown in 15-cm-diameter culture plates until confluence. CoQ 10 was extracted in a hexane:ethanol mixture (48) . The lipid component of the extract was separated by high-performance liquid chromatography (HPLC) on a reverse Symmetry ® C18 3.5 µm, 4.6 × 150 mm column (Waters), using a mobile phase consisting of methanol, ethanol, 2-propanol, acetic acid (500:470:15:15) and 50 m sodium acetate at a flow rate of 0.8 ml/min. The electrochemical detector consisted of an ESA Coulochem II with the following setting: guard cell (upstream of the injector) at +900 mV, conditioning cell at −650 mV (downstream of the column), followed by the analytical cell at +450 mV. CoQ 10 concentration was estimated by comparison of the peak area with those of standard solutions of known concentration, and the results were normalized to mg protein.
CoQ 10 biosynthesis assays
We performed biochemical assays to measure incorporation of two radiolabeled substrates (49) . For the first assay, AOA1 and control fibroblasts were plated in six-well plates (40 000 cells/ well) and were cultured using DMEM with 10% fetal calf serum. After 2 days, the medium was replaced by fresh DMEM with 0.1 μCi of 14 C-PHB (50 Ci/mol specific activity). After incubation for additional 24 h, cells were washed twice with phosphate-buffered saline (PBS) and collected by using 0.5 ml of 1% sodium dodecyl sulfate (SDS), followed by shaking for 10 min at room temperature (twice). The contents of each plate were combined (3 ml total), and 0.2 ml was saved for protein determination. The remaining pooled suspensions were subjected to hexane extraction. CoQ 10 was extracted adding 4 ml hexane-ethanol (5/2 v/v) and vortexing for 2 min. After centrifugation at 2500 rpm at room temperature for 5 min, the upper phase was carefully transferred into a 20-ml glass scintillation vial. The combined extract was evaporated under a gentle stream of N 2 gas, and the residue was dissolved in 0.15 ml of 1-propanol. Fifty microliters of the extract was directly injected into the HPLC. The waste line of HPLC was connected to a fraction collector, programed to collect 1.0 ml of fractions per minute. CoQ 10 peak was identified by specific retention time determined after injection of a known amount of authentic CoQ 10 . The amount of radioactivity in the collected fraction was determined in a Packard scintillation counter.
In the second assay, the incubation mixture contained 250 nCi of 3 H-radiolabeled decaprenyl pyrophosphate (decaprenyl-PP) (20 Ci/mmol) solubilized in 25 µl of 1% Triton X-100, 50 m potassium phosphate, pH 7.5, 10 m MgCl 2 , 5 m ATP, 20 µ 4-hydroxybenzoic acid and fibroblast lysate (1 mg protein) in a total volume of 0.5 ml. After incubation at 37°C in a shaking water bath for 60 min, the reaction was stopped by adding 1 ml of ethanol, followed by 1 ml of 0.1  SDS. Hexane extraction was carried out as mentioned earlier, and the residue was dissolved in 100 µl of 1-propanol. An aliquot of 50 µl was injected into the HPLC. Fraction collection and radioactivity measurement were performed as described earlier.
Mitochondrial respiratory chain enzymes activity
The activity of mitochondrial respiratory chain enzymes was assessed spectrophotometrically (50) . NADH cytochrome c reductase (NCCR) activity (Complex I + III) was measured by monitoring the rate of reduced cytochrome c formation using NADH as substrate. Changes in absorbance at 550 nm were monitored at 30°C over 1 min, followed by the addition of 10 μ rotenone and additional monitoring of absorbance for 2 min. Reduction of cytochrome c was determined based on the difference between the rate of absorbance change before and after rotenone was added. Succinate cytochrome c reductase (SCCR) activity (Complex II + III) was measured by monitoring the rate of reduced cytochrome c formation using succinate as substrate. Changes in absorbance were monitored at 30°C for 2 min at 550 nm. SDH (CII) activity was measured following reduction of 2,6-dichlorophenol-indophenol (DCIP) at 600 nm for 1 min. CS activity was measured following the reduction of 1 m 5,5′-dithiobis (2-nitrobenzoic acid) at 412 nm (30°C) for 2 min. Enzymes activities were normalized to proteins.
OCR and ECAR measurements
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in AOA1 and control fibroblasts were measured with an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). Coupling efficiency was assessed by the reduction in oxygen consumption after oligomycin injection, as the fraction of basal mitochondrial oxygen consumption used for ATP synthesis. Cell respiratory control ratio is the ratio of the uncoupled OCR [after addition of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)] to OCR in the presence of oligomycin. Because it is the ratio of two rates, this parameter, as well as coupling efficiency, is sensitive to the sites of dysfunction and therefore is internally normalized (51) . Each cell line was seeded in five wells of an XF 24-well cell culture microplate (Seahorse Bioscience) at a density of 60 000 cells/well. Forty minutes before the assay, growth medium was replaced with 525 μl of bicarbonate-free DMEM pre-warmed at 37°C. After baseline measurements of OCR (OCR-B), OCR was measured after sequentially injection to each well of 75 μl of oligomycin (OL), 75 μl of FCCP and 75 μl of rotenone and antimycin A, to reach working concentrations of 1, 0.75, 1 and 1 μ, respectively. Non-mitochondrial respiration was subtracted from all the rates before analysis.
COQ gene expression by real-time PCR
Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to measure the expression of genes required for CoQ 10 biosynthesis (COQ genes). Total RNA was extracted from cells using PureLink TM RNA Mini Kit (Ambion) according to the manufacturer''s instructions. Purified total RNA (100 ng) was reverse-transcribed to cDNA with SuperScript ® VILO™ cDNA Synthesis Kit (Invitrogen) after digestion with DNase I (Roche). Quantitative RT-PCR was performed using TaqMan ® Assays for each gene (Applied Biosystems, Invitrogen).
The expression of the target genes was calculated by delta-Ct method and normalized to the expression of β-actin.
Immunoblotting analyses
Cell lysates were quantitated for total protein content using the Bradford system (ThermoScience) and analyzed by electrophoresis in an SDS 4-20% gradient polyacrylamide gel. After electrophoresis, proteins were transferred electrophoretically to polyvinylidene difluoride membrane and probed with the following antibodies: anti-PDSS1 (3 μg/mL, Sigma), anti-APTX (1:1000, Abcam), anti-β-actin (1:50 000, Sigma), anti-vinculin (1:10 000, Sigma), anti-APE1 (1:1500, Abcam), anti-NRF1 (1:300, Santa Cruz), anti-NRF2 (1:500, Santa Cruz), anti-PARP1 (1:1500, BioRad), anti-SDHA (CII, 1:1000, Abcam), anti-TOM20 (1:1000, Santa Cruz) and anti-CoQ5 (1:200, Thermo Scientific). Peroxidase-conjugated anti-rabbit, anti-goat or anti-mouse IgG secondary antibodies (Santa Cruz Biotechnology) were used at a dilution of 1:2000, 1:10 000 and 1:5000, respectively. Protein bands were visualized by chemiluminescence, using reagents purchased from GE Healthcare. Intensity of the bands was quantified with ImageJ.
Generation of cells expressing shRNA/NRF1-overexpressing shAPTX cells
Hela cells were cultured in DMEM with 10% FBS until 70-80% confluent. Transfections with scramble shRNA-pLKO plasmid (used as control), APTX-specific TRC shRNA-pLKO plasmid construct (TRCN0000083642; Sigma), APE1-specific TRC shRNA-pLKO plasmid construct (TRCN00007958), ORF expression clone for NRF1 (BC016925.1) and empty control vector for pReceiver-M02 (used as control) were mediated by Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 5 h of transfection, cells were selected with puromycin/neomycin in DMEM 2% FBS and transfected clones expanded separately with DMEM 10% FBS.
Statistical analysis
Statistical analyses were performed with GraphPad InStat. Shapiro-Wilk normality test was performed to assess the normality of the population distribution. Student's t-test or Mann-Whitney tests were used to assess significant differences. A P-value of <0.05 was considered to be statistically significant. Data were expressed as the mean ± SEM.
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